MedTrace Logo

Genomic Imprinting Testing for Diagnosis of Bladder Cancer

NCT03563443 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-06-20

No results posted yet for this study

Summary

Urine analysis provide a promising non-invasive liquid biopsy for diagnosis of bladder cancer. Molecular biomarkers in urine may serve as important diagnostic and prognostic indicators for bladder cancer. Many alterations of genes and proteins have been identified in the urinary for diagnosis of bladder cancer. However, not all bladder cancer patients have the same alterations due to tumor heterogeneity. Thus, to reach satisfactory sensitivity and specificity a new diagnostic molecular alteration should exists ubiquitously in cancers. Numerous studies indicate that Loss of imprinting (LOI) exists ubiquitously in cancers and precede morphological changes. The investigators will conduct a prospective evaluation of a panel of LOI changes in urine test for detection and surveillance of bladder cancer patients.

Conditions

Interventions

DIAGNOSTIC_TEST

Genomic Imprinting Testing

The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)

Sponsors & Collaborators

  • LiSen imprinting diagnostic (LSID) Company

    collaborator UNKNOWN

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Chuangliang Xu, M.D., Ph.D · Changhai Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2018-12-15
Completion
2019-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03563443 on ClinicalTrials.gov